Cognizant Technology Solutions Corp. Stock Remains Steady Friday, Underperforms Market

MacroGenics Inc

Change company Symbol lookup

Select an option...

MGNX MacroGenics Inc

CBZ CBIZ Inc

PSEC Prospect Capital Corp

SPEC Spectralcast Inc

RC Ready Capital Corp

GNK Genco Shipping & Trading Ltd

NVOS Novo Integrated Sciences Inc

PDRDF Pernod Ricard SA

RKDA Arcadia Biosciences Inc

BBVA Banco Bilbao Vizcaya Argentaria SA

Health Care : Biotechnology | Small Cap Value

Company profile

MacroGenics, Inc. is a biopharmaceutical company that is focused on developing and commercializing antibody-based therapeutics for the treatment of cancer. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is MGC018, an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. It is also developing enoblituzumab, an Fc-optimized monoclonal antibody (mAb) that targets B7-H3 and molecules that target programmed cell death protein 1 (PD-1), a protein that is important in the regulation of the immune system's response to cancer. Its clinical pipeline includes two bispecific DART product candidates that co-engage both PD-1 and lymphocyte-activation gene 3 (LAG-3) (tebotelimab), and PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (lorigerlimab). In addition, it is also developing MGD024.

Cognizant Technology Solutions Corp. Stock Remains Steady Friday, Underperforms Market

4:47 pm ET January 14, 2022 (MarketWatch) Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Cognizant Technology Solutions Corp. (CTSH) were unchanged Friday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index rising 0.08% to 4,662.85 and the Dow Jones Industrial Average falling 0.56% to 35,911.81. Cognizant Technology Solutions Corp. closed $4.83 below its 52-week high ($92.03), which the company achieved on January 4th.

The stock demonstrated a mixed performance when compared to some of its competitors Friday, as Accenture PLC Cl A (ACN) fell 2.22% to $353.36, International Business Machines Corp. (IBM) fell 0.41% to $134.21, and Infosys Ltd. ADR (500209.BY) rose 2.34% to $26.20. Trading volume (2.3 M) remained 355,113 below its 50-day average volume of 2.7 M.

Data source: Dow Jones Market Data, FactSet. Data compiled Janurary 14, 2022.

-MarketWatch Automation

(END) Dow Jones Newswires

January 14, 2022 16:47 ET (21:47 GMT)